ClinicalTrials.gg
RecruitingNCT06541652FFCD-2205Updated Aug 5, 2025

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

An observational study in Hepatocholangiocarcinoma, Fibrolamellar Carcinoma and Hepatic Epithelioid Hemangioendothelioma, sponsored by Federation Francophone de Cancerologie Digestive. Recruiting at 40 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Federation Francophone de Cancerologie Digestive · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.

Planned enrollment
17th of 26
150 · median 303
Started
2024
with 2 others
Observational
26 of 93
11 open now
Primary completion
2026-02
later than 7 of 27 live
Registered
87th of 93
by date
Lead sponsor
6 of 93
Federation Francophone de Cancerologie Digestive

Among the 93 studies in Liver Neoplasms with a site in France, this one is the 17th largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2024, is one of 26 observational ones, reaches primary completion later than 7 of the 27 other live ones, and was the 87th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Liver Neoplasms with a site in France, or all of them as a file.
02

Study summary

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Read the detailed description

The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

03

Conditions studied

  • Hepatocholangiocarcinoma
  • Fibrolamellar Carcinoma
  • Hepatic Epithelioid Hemangioendothelioma
  • Hepatoblastoma
  • Hepatic Neuroendocrine Carcinoma
  • Hepatic Carcinosarcomas
  • Hepatic Cystadenoma
  • Hepatic Leiomyosarcomas
  • Hepatic Angiosarcomas
  • Cholangiocarcinoma

Keywords

  • rare primary liver cancers
  • LIVER
  • HEPATIC
  • COHORT
  • RISK FACTORS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In the health centers, patients were identified in two ways:

  1. via diagnoses obtained in the anatomopathology departments of each investigating center
  2. via multidisciplinary consultation meetings on primary hepatic tumours/digestive oncology at each investigating center.

Patients with a diagnosis of rare primary hepatic cancers diagnosed on or after 01/01/2018 may be included, whether alive or deceased at the time of registration in the CAPRIH cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older,
  • with proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
  • diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
  • for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion criteria

Exclusion Criteria:

  • without social security
  • No access to tumor block
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

    Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

    Time frame: up to 5 years from the date of diagnosis

Secondary outcomes

  1. Recurrence-free survival (for non-metastatic patients)

    Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news

    Time frame: up to 5 years from diagnosis

  2. Progression-free survival (for metastatic patients)

    Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.

    Time frame: up to 5 years from diagnosis

  3. Overall survival

    Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.

    Time frame: up to 5 years from diagnosis

07

Study locations

29 of 40 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2026, 23 months after the start.

Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 23 months is below that.

Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Aug 7, 2024
StartActual
Mar 26, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2031
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06541652
Lead sponsor
Federation Francophone de Cancerologie Digestive
Collaborators
Société Nationale Française de Gastroentérologie
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Mar 26, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2031 (estimated)
Last update
Aug 5, 2025

Study contacts

lila gaba
Contact
lila.gaba@u-bourgogne.fr
06 99 78 84 73
jean-charles nault, Pr
principal investigator · Federation Francophone de Cancerologie Digestive

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion